Latest news with #BSEHealthcareindex
Business Standard
3 days ago
- Business
- Business Standard
Astrazeneca Pharma India Ltd Spurts 7.28%
Astrazeneca Pharma India Ltd has added 2.1% over last one month compared to 1.8% gain in BSE Healthcare index and 0.88% rise in the SENSEX Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare index is up 0.34% to quote at 42749.54. The index is up 1.8 % over last one month. Among the other constituents of the index, Orchid Pharma Ltd increased 3.84% and Cohance Lifesciences Ltd added 1.94% on the day. The BSE Healthcare index went up 22.53 % over last one year compared to the 9.81% surge in benchmark SENSEX. Astrazeneca Pharma India Ltd has added 2.1% over last one month compared to 1.8% gain in BSE Healthcare index and 0.88% rise in the SENSEX. On the BSE, 1001 shares were traded in the counter so far compared with average daily volumes of 913 shares in the past one month. The stock hit a record high of Rs 9199 on 24 Apr 2025. The stock hit a 52-week low of Rs 5415.55 on 04 Jun 2024.
Time of India
3 days ago
- Business
- Time of India
New launches to drive Sun Pharma's future growth; PAT may take a hit by tax surge
Sun Pharmaceutical Industries has underperformed the BSE Healthcare index over a one-month and three-month periods amid the likely pressure on profitability in the coming quarters. While the company expects to retain the revenue growth momentum for FY26 after clocking 8% growth in FY25, its plan to spend over $100 million in marketing and promotion of specialty products is expected to dent profitability for the current fiscal year. Analysts have slashed FY26 EPS targets by 3-8%. The company's net profit fell by 19% year-on-year to Rs2,149.9 crore for the March quarter due to higher tax outgo. Revenue grew by 8% to Rs12,958.8 crore. The tax expense for the quarter was Rs1,093.7 crore compared to Rs148.9 crore a year ago. The company expects the tax expense to increase further in FY26, due to exhaustion of tax loss from previous accounting periods. The operating margin before depreciation and amortisation (EBITDA margin) improved to 28.7% in the March 2025 quarter from 25.3% in the year-ago quarter. For the full year, the company's revenue and net profit grew by 9% and 14% to Rs52,041.3 crore and Rs10,929 crore respectively. The research & development (R&D) expense was Rs3,248.4 crore for FY25, representing 6.4% of sales. It is expected to be 6-8% of sales for next fiscal year. The pharma company has guided for a mid-to-high single digit year-on-year revenue growth in FY26. The company expanded market share in the domestic formulations business to 8.3% in the March quarter from 8%a year ago. In the September 2025 quarter, Sun Pharma is expected to launch Leqselvi (deuruxolitinib),which is used to treat severe alopecia areata, a type of hair loss. Elara Capital estimates the drug to be more than $200million product in three-four years. In FY26, the company also plans to launch Unloxcyt (cosibelimab), a drug developed by the US based Checkpoint Therapeutics, which it acquired in March 2025 for $355 million. The company is seeking partners to further develop and commercialize MM-II (Large Liposomes of DPPC and DMPC) for select geographies. Phase 3 clinical trials are underway for this drug. 'It has been implementing efforts to not only expand offerings but also enhance marketing franchise in regulated markets for differentiated products,' Motilal Oswal Financial Services said in a report. The brokerage has reduced its earnings estimates by 3% and 1% for FY26 and FY27, considering the additional expense on specialty products marketing . It expects earnings to grow by 17% annually FY25-27. It has maintained 'BUY' with a target price of Rs2,000. On Friday, the stock was last traded at Rs1,678.3 on the BSE.
Business Standard
23-05-2025
- Business
- Business Standard
Windlas Biotech Ltd Slips 4.88%, BSE Healthcare index Shed 1.03%
Windlas Biotech Ltd has lost 9.89% over last one month compared to 1.44% fall in BSE Healthcare index and 1.1% rise in the SENSEX Windlas Biotech Ltd fell 4.88% today to trade at Rs 923. The BSE Healthcare index is down 1.03% to quote at 42080.34. The index is down 1.44 % over last one month. Among the other constituents of the index, Sun Pharmaceutical Industries Ltd decreased 4.08% and Indoco Remedies Ltd lost 3.58% on the day. The BSE Healthcare index went up 18.11 % over last one year compared to the 7.4% surge in benchmark SENSEX. Windlas Biotech Ltd has lost 9.89% over last one month compared to 1.44% fall in BSE Healthcare index and 1.1% rise in the SENSEX. On the BSE, 1506 shares were traded in the counter so far compared with average daily volumes of 5266 shares in the past one month. The stock hit a record high of Rs 1197 on 06 Nov 2024. The stock hit a 52-week low of Rs 552.85 on 04 Jun 2024.
